Authors' objectives: Cytomegalovirus (CMV) is a common viral infection which is carried by around 50% of the population and causes no harm to healthy people. However, for people undergoing blood or bone marrow transplantation it can cause serious complications due to their reduced immunity to infection. Cytovir CMV is a new treatment that aims to prevent and treat CMV infection following blood or marrow transplantation. It is made up of immune cells that specifically attack CMV and it is administered by intravenous infusion. Cytovir CMV is currently being studied to see how well it works and whether it is safe to use in people who have undergone blood or marrow transplantation. It is already available to specialist transplant centres in the UK.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/cytovir-cmv-for-cytomegalovirus-infection-in-patients-undergoing-allogeneic-haematopoietic-stem-cell-transplantation/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)